SCHEMBL30830919

SCHEMBL30830919

CN1C[C@H](Nc2cnn(C)c(=O)c2Br)C[C@H](c2ccc(CN3CCN(c4cc5c(cc4F)C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 9/20 0.50
▸ KAT2B Q92831 8/20 0.49
▸ BRD9 Q9H8M2 3/20 0.49
▸ BRD1 O95696 1/20 0.49
▸ ACHE P22303 1/20 0.49
▸ BRPF1 P55201 1/20 0.49
▸ BPTF Q12830 1/20 0.49
▸ KAT2A Q92830 1/20 0.49
▸ BRD7 Q9NPI1 1/20 0.49
▸ BAZ2B Q9UIF8 1/20 0.49
▸ BRPF3 Q9ULD4 1/20 0.49
▸ IKZF3 Q9UKT9 8/20 0.44
▸ DDB1 Q16531 7/20 0.44
▸ PLK4 O00444 1/20 0.39
▸ AR P10275 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ ADRA1B P35368 1/20 0.38
▸ EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830669 0.93 CRBN (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830775 0.93 CRBN (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830707 0.90 KAT2B (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830931 0.89 KAT2B (0.51) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830848 0.89 CRBN (0.50) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830894 0.88 KAT2B (0.49) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830983 0.87 KAT2B (0.55) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830766 0.87 KAT2B (0.55) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830516 0.87 KAT2B (0.53) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830906 0.85 KAT2B (0.52) CRBNKAT2BBRD9BRD1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback